A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

Cancer

Volumn 85, Issue 6, 1999, Pages 1284-1292

  Ingle, James N ^a   Suman, Vera J ^a   Kardinal, Carl G ^b   Krook, James E ^c   Mailliard, James A ^d   Veeder, Michael H ^e   Loprinzi, Charles L ^a   Dalton, Robert J ^c   Hartmann, Lynn C ^a   Conover, Cheryl A ^a   Pollak, Michael N ^f  

^a MAYO CLINIC   (United States)

^b Alton Ochsner   (United States)

^c Duluth CCOP   (United States)

^d MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^e Illinois Oncol Res Assoc CCOP   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Breast carcinoma; Hormonal; Insulin like growth factor I; Metastatic; Octreotide; Postmenopausal; Tamoxifen

Indexed keywords

OCTREOTIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEATORRHEA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; SURVIVAL RATE; TAMOXIFEN;

EID: 0033559620     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1284::AID-CNCR10>3.0.CO;2-P     Document Type: Article

References (27)

1. Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 1996;77:683-90.
2. Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Rev 1987;8:29-43.
3. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987;47: 1566-70.
4. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Antiproliferative effects of somatostatin and the somatostatin analogue SMS 201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 1988;114:306-8.
5. Schally AV, Redding TW, Cai RZ, Paz JI, Ben-David M, Comaru-Schally AM. Somatostatin analogues in the treatment of various experimental tumors. In: Klijn JGM et al. Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents, New York: Raven Press, 1987: 431-40.
6. Lamberts SWJ. Non-pituitary actions of somatostatin: a review on the therapeutic role of SMS 201-995 (Sandostatin). Acta Endocrinol (Copenh) 1986;112(Suppl 276):41-55.
7. Lamberts SWJ, Uitterlinden P, del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 1987;65:703-10.
8. Furlanetto RW, DiCarlo JN. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res 1984;44:2122-8.
9. Pollak MN, Polychronakos C, Yousefi S, Richard M. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 1988; 154:326-31.
10. Pollak M, Constantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-7.
11. Ingle JN, Kardinal CG, Suman VJ, Krook JE, Hatfield AK. Octreotide as first-line treatment for women with metastatic breast cancer. Invest New Drugs 1996;14:235-7.
12. American Joint Committee on Cancer. Breast In: Beahrs OH, Henson DE, Hutter RVP, Myers MH. Manual for staging of cancer. Third edition. Philadelphia: J. B. Lippincott, 1988:145-50.
13. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
14. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, et al. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res 1997;3:1713-20.
15. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method of titration of the binding proteins and competitive binding studies. Anal Biochem 1986; 154:138-43.
16. Fisher RA. Statistical methods for research workers. Edinburgh: Oliver and Boyd, 1925.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Peto R, Peto J. Asymptotically efficient rank invariant test procedures [with discussion]. J R Stat Soc [A] 1972;35:185-207.
19. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-202.
20. Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika 1967;54:167-79.
21. Gibbons JD. Nonparametric statistical inference. New York: McGraw-Hill, 1971.
22. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogues. Proc Soc Exp Biol Med 1998;217: 143-52.
23. Pollak MN, Ingle I, Suman V, Kugler J. Rationale for combined antiestrogen-somatostatin analogue therapy of breast cancer. In: Salmon SE. Adjuvant therapy of cancer VIII. Philadelphia: Lippincott-Raven, 1997;145-52.
24. Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Comm 1994;203:253-9.
25. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz (a)anthracene-induced rat mammary carcinomas. Cancer Res 1994;54:6334-7.
26. Pollak M. Enhancement of the antineoplastic effects of tamoxifen by somatostatin analogues. Digestion 1996; 57(Suppl 1):29-33.
27. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53:681-99.